Dhvanit Shah, Garuda Therapeutics CEO

Blood stem cell ther­a­py mak­er Garu­da nabs $62M

Garu­da Ther­a­peu­tics brought in $62 mil­lion via a Se­ries B to take its off-the-shelf cell ther­a­pies in­to the clin­ic next year.

The Boston-area biotech wants to rid the need for blood stem cell trans­plants and in­stead give pa­tients self-re­new­ing blood stem cells. The pro­ceeds, which add to a $72 mil­lion Se­ries A from Sep­tem­ber 2021, will bankroll two lead pro­grams in hema­to­log­i­cal and on­col­o­gy in­di­ca­tions, Garu­da said Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.